SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Cowen & Company 30th Annual Healthcare Conference.  The details are as follows:  

Date:  Tuesday, March 9, 2010

Time:  3:45 PM Eastern

Location: Boston Marriott Copley Place

Speaker: Michael Narachi, Chief Executive Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Back to top

RELATED LINKS
http://www.orexigen.com/